alzAPOE therapeutics change feed
Snapshot

Where things stand

Tracked therapeutics
12

4 in clinical development, 2 approved

Readouts in 12 months
2

8 pending overall

Next readout
1 Sep 2026

AGB101 — in 1 month

Curated studies
23

3 without posted dates

What changed

All 230 changes →

Most consequential first — 0 high, 3 medium, 227 low in this snapshot. Newest detection 2 days ago.

  2. mediumunreviewedtrialctgov

    A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease

    new study registeredNCT06996730

  4. mediumunreviewedtrialctgov

    Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

    new study registeredNCT06911944

  6. mediumunreviewedtrialctgov

    Cognitive Neurology Unit Clinical Registry

    new study registeredNCT05925621

Development stage

Shade tracks stage along a single-hue ramp that deepens with the ladder, and inverts in dark mode. Stage is the therapeutic's own curated status, not an inference from its trials.

  1. Preclinical

    6

  2. Phase 1

    1

  3. Phase 2

    1

  4. Phase 3

    2

  5. Approved

    2

Next readouts

Pending primary completions, soonest first. Dates in the future are the sponsor's current estimate and slip routinely — they are not commitments.

TherapeuticStudyPhaseStatusEnrolmentPrimary completionDue in
AGB101NCT05824728PHASE2RECRUITING301 Sep 20261 mo
AGB101NCT06919926PHASE2RECRUITING601 May 20279 mo
lecanemabNCT05925621—RECRUITING5001 Jun 202822 mo
LX1001NCT05400330PHASE1ACTIVE NOT RECRUITING101 Nov 202827 mo
lecanemabNCT04468659PHASE3ACTIVE NOT RECRUITING1,40021 Dec 202829 mo
donanemabNCT06911944PHASE4NOT YET RECRUITING6031 Dec 202829 mo
lecanemabNCT03887455PHASE3ACTIVE NOT RECRUITING1,90630 Jun 202935 mo
donanemabNCT06996730PHASE2/PHASE3NOT YET RECRUITING2401 Jun 203046 mo

Not scheduled: donanemab NCT03367403, donanemab NCT05026866, donanemab NCT07602582 — no posted start or completion date, so they are absent from both views here.

Full schedule

Every dated study, running start to primary completion. Solid is elapsed; an open outline is projected. A study that has not begun draws no solid span at all, and its projection starts at today rather than at a posted start date that has already slipped past. A terminated study stops where it stopped; a withdrawn one never enrolled anyone, so it is a tick at its start date rather than a span. The posted completion date stays in the text either way. Shade uses the same single-hue ramp as the stage grid, but here it encodes trial phase rather than development stage — the two scales are not interchangeable, and a combined “Phase 2/3” study takes its higher phase.

  1. AGB101NCT05824728PHASE2RECRUITING1 Sep 2026
  2. AGB101NCT06919926PHASE2RECRUITING1 May 2027
  3. lecanemabNCT05925621—RECRUITING1 Jun 2028
  4. LX1001NCT05400330PHASE1ACTIVE NOT RECRUITING1 Nov 2028
  5. lecanemabNCT04468659PHASE3ACTIVE NOT RECRUITING21 Dec 2028
  6. donanemabNCT06911944PHASE4NOT YET RECRUITING31 Dec 2028
  7. lecanemabNCT03887455PHASE3ACTIVE NOT RECRUITING30 Jun 2029
  8. donanemabNCT06996730PHASE2/PHASE3NOT YET RECRUITING1 Jun 2030
  9. AGB101NCT05986721PHASE2WITHDRAWN1 Jul 2028
  10. ALZ-801 (valiltramiprosate)NCT06304883PHASE3TERMINATED11 Mar 2026
  11. semaglutide (oral)NCT04777396PHASE3COMPLETED16 Sep 2025
  12. semaglutide (oral)NCT04777409PHASE3COMPLETED15 Sep 2025
  13. lecanemabNCT01767311PHASE2COMPLETED10 Dec 2024
  14. LX1001NCT03634007PHASE1/PHASE2COMPLETED7 Nov 2024
  15. ALZ-801 (valiltramiprosate)NCT04770220PHASE3COMPLETED29 May 2024
  16. ALZ-801 (valiltramiprosate)NCT04693520PHASE2COMPLETED20 Jun 2023
  17. AGB101NCT03486938PHASE2/PHASE3COMPLETED2 Nov 2022
  18. donanemabNCT05108922PHASE3COMPLETED9 Sep 2022
  19. ALZ-801 (valiltramiprosate)NCT04157712PHASE1COMPLETED4 Jul 2016
  20. ALZ-801 (valiltramiprosate)NCT04585347PHASE1COMPLETED13 Nov 2015